Business Context and Reporting Period
This Form 8-K was filed by Altimmune, Inc. on June 22, 2017, reporting a corporate governance event. The filing addresses the re-engagement of an independent registered public accounting firm following the company's business combination with PharmAthene, Inc., which was completed on May 4, 2017.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a disclosure regarding the appointment of an auditor and does not contain financial performance data.
Material Changes
The primary material change disclosed is the appointment of Ernst & Young LLP (E&Y) as the Company's independent registered public accounting firm effective June 22, 2017. E&Y had previously served as the principal accountant for PharmAthene, Inc. prior to the May 4, 2017 merger. The Company did not re-engage E&Y immediately after the merger but has now done so to audit financial statements.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. Regarding risks and contingencies, the Company explicitly states that during the period between the merger (May 4, 2017) and the re-engagement date (June 22, 2017), there were no consultations with E&Y regarding the application of accounting principles to specified transactions or any matters involving disagreements or reportable events.
Investor Verification Checklist
- Verify the effective date of the new audit engagement with Ernst & Young LLP (June 22, 2017).
- Confirm the timeline of the auditor gap between the PharmAthene merger (May 4, 2017) and the re-engagement.
- Review the absence of any reported disagreements or reportable events with the former auditor during the interim period.
- Note that this filing does not contain updated financial results; refer to the most recent 10-Q or 10-K for financial metrics.